RU2344123C9 - 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора - Google Patents
3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора Download PDFInfo
- Publication number
- RU2344123C9 RU2344123C9 RU2003133448/04A RU2003133448A RU2344123C9 RU 2344123 C9 RU2344123 C9 RU 2344123C9 RU 2003133448/04 A RU2003133448/04 A RU 2003133448/04A RU 2003133448 A RU2003133448 A RU 2003133448A RU 2344123 C9 RU2344123 C9 RU 2344123C9
- Authority
- RU
- Russia
- Prior art keywords
- group
- substituted
- alkyl
- unsubstituted
- groups
- Prior art date
Links
- -1 3,4-disubstituted cyclobutene-1,2-diones Chemical class 0.000 title claims 5
- 239000003446 ligand Substances 0.000 title claims 2
- 108091008928 CXC chemokine receptors Proteins 0.000 title 1
- 102000054900 CXCR Receptors Human genes 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 20
- 239000012453 solvate Substances 0.000 claims abstract 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 5
- 239000003814 drug Substances 0.000 claims abstract 5
- 230000001404 mediated effect Effects 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 55
- 150000001875 compounds Chemical class 0.000 claims 54
- 125000001072 heteroaryl group Chemical group 0.000 claims 39
- 125000001424 substituent group Chemical group 0.000 claims 36
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 21
- 125000003107 substituted aryl group Chemical group 0.000 claims 17
- 125000004432 carbon atom Chemical group C* 0.000 claims 15
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 13
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims 1
- 108050006947 CXC Chemokine Proteins 0.000 claims 1
- 102000019388 CXC chemokine Human genes 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000004946 alkenylalkyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 125000005038 alkynylalkyl group Chemical group 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003388 anti-hormonal effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000005750 substituted cyclic group Chemical group 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 abstract 2
- 108010012236 Chemokines Proteins 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 208000037976 chronic inflammation Diseases 0.000 abstract 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 0 CC(*)(*)*=CSC=CN Chemical compound CC(*)(*)*=CSC=CN 0.000 description 21
- MXXPDAXFPXOUBG-UHFFFAOYSA-O CC(C)C(C)C(C)[NH3+] Chemical compound CC(C)C(C)C(C)[NH3+] MXXPDAXFPXOUBG-UHFFFAOYSA-O 0.000 description 1
- LLEOJEJGAJNCLX-UHFFFAOYSA-N CCC(C)NC(C(C1=O)=O)=C1Nc(cccc1C(N(C)C)=O)c1O Chemical compound CCC(C)NC(C(C1=O)=O)=C1Nc(cccc1C(N(C)C)=O)c1O LLEOJEJGAJNCLX-UHFFFAOYSA-N 0.000 description 1
- YZNQZONEXPPIBE-QMMMGPOBSA-N CC[C@H](C(F)(F)F)c1cc(CC)c[o]1 Chemical compound CC[C@H](C(F)(F)F)c1cc(CC)c[o]1 YZNQZONEXPPIBE-QMMMGPOBSA-N 0.000 description 1
- LLEOJEJGAJNCLX-VIFPVBQESA-N CC[C@H](C)NC(C(C1=O)=O)=C1Nc(cccc1C(N(C)C)=O)c1O Chemical compound CC[C@H](C)NC(C(C1=O)=O)=C1Nc(cccc1C(N(C)C)=O)c1O LLEOJEJGAJNCLX-VIFPVBQESA-N 0.000 description 1
- JGGJMYCQINJGFS-NKWVEPMBSA-N CC[C@](C(C)C)(P)[IH][C@@H](N)I Chemical compound CC[C@](C(C)C)(P)[IH][C@@H](N)I JGGJMYCQINJGFS-NKWVEPMBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28402601P | 2001-04-16 | 2001-04-16 | |
| US60/284,026 | 2001-04-16 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2003133448A RU2003133448A (ru) | 2005-06-10 |
| RU2344123C2 RU2344123C2 (ru) | 2009-01-20 |
| RU2344123C9 true RU2344123C9 (ru) | 2009-05-20 |
Family
ID=23088576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003133448/04A RU2344123C9 (ru) | 2001-04-16 | 2002-04-15 | 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP1381590B1 (enExample) |
| JP (3) | JP4499993B2 (enExample) |
| KR (2) | KR100952531B1 (enExample) |
| CN (2) | CN1289471C (enExample) |
| AR (1) | AR035825A1 (enExample) |
| AT (2) | ATE365154T1 (enExample) |
| AU (3) | AU2002311841B2 (enExample) |
| BR (1) | BRPI0208957B8 (enExample) |
| CA (1) | CA2444031C (enExample) |
| CY (2) | CY1109908T1 (enExample) |
| CZ (1) | CZ20032831A3 (enExample) |
| DE (2) | DE60235507D1 (enExample) |
| DK (2) | DK1818325T3 (enExample) |
| EC (1) | ECSP034809A (enExample) |
| ES (2) | ES2340207T3 (enExample) |
| HU (1) | HUP0401783A3 (enExample) |
| IL (3) | IL158262A0 (enExample) |
| MX (1) | MXPA03009441A (enExample) |
| MY (2) | MY138202A (enExample) |
| NO (2) | NO330790B1 (enExample) |
| NZ (3) | NZ529551A (enExample) |
| PE (1) | PE20021084A1 (enExample) |
| PL (2) | PL208928B1 (enExample) |
| PT (2) | PT1381590E (enExample) |
| RU (1) | RU2344123C9 (enExample) |
| SI (2) | SI1818325T1 (enExample) |
| SK (1) | SK287598B6 (enExample) |
| TW (2) | TWI316930B (enExample) |
| WO (1) | WO2002083624A1 (enExample) |
| ZA (1) | ZA200307905B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2784831C2 (ru) * | 2018-09-21 | 2022-11-30 | Пфайзер Инк. | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, пригодные в качестве ингибиторов ccr6 |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| MXPA04003439A (es) | 2001-10-12 | 2004-07-08 | Schering Corp | Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc. |
| US8246969B2 (en) | 2001-11-16 | 2012-08-21 | Skinmedica, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| WO2003080053A1 (en) * | 2002-03-18 | 2003-10-02 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
| GB0218326D0 (en) * | 2002-08-07 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| US20040186142A1 (en) | 2002-10-09 | 2004-09-23 | Schering Corporation Pharmacopeia, Inc. | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
| DE502004009440D1 (de) | 2003-04-03 | 2009-06-10 | Merck Patent Gmbh | Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen |
| CA2522748C (en) * | 2003-04-18 | 2011-06-28 | Schering Corporation | Synthesis of 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide |
| BRPI0412259B1 (pt) | 2003-07-22 | 2019-08-20 | Astex Therapeutics Limited | Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica |
| GB0320983D0 (en) * | 2003-09-08 | 2003-10-08 | Biofocus Plc | Compound libraries |
| DE602004024798D1 (de) | 2003-09-23 | 2010-02-04 | Fermion Oy | Herstellung von quetiapin |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| JP4939229B2 (ja) | 2003-12-19 | 2012-05-23 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール |
| JP4851943B2 (ja) | 2003-12-22 | 2012-01-11 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド |
| CN1914187B (zh) * | 2004-01-30 | 2012-01-25 | 先灵公司 | Cxc趋化因子受体配位体的结晶多晶型物 |
| EP1742914A1 (en) * | 2004-02-27 | 2007-01-17 | Schering Corporation | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
| CA2576170A1 (en) | 2004-08-16 | 2006-03-02 | The Procter & Gamble Company | 2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof |
| EP1634573A1 (en) * | 2004-08-16 | 2006-03-15 | The Procter and Gamble Company | 2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof |
| EP1804799B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
| CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
| MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| AR051094A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| EP1807085B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| CN101083982A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物 |
| ATE432921T1 (de) | 2004-12-23 | 2009-06-15 | Gpc Biotech Ag | Quadratsäurederivate mit antiproliferativer wirkung |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| BRPI0611187A2 (pt) | 2005-06-03 | 2010-08-24 | Xenon Pharmaceuticals Inc | derivados aminotiazàis como inibidores da estearoil-coa desaturase humana |
| WO2007002764A2 (en) * | 2005-06-29 | 2007-01-04 | Schering Corporation | Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
| WO2007005403A1 (en) | 2005-06-29 | 2007-01-11 | Schering Corporation | 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands |
| DE102005035742A1 (de) * | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| LT1951663T (lt) * | 2005-11-24 | 2016-11-10 | Dompé Farmaceutici S.P.A. | (r)-arilalkilamino dariniai ir juos turinčios farmacinės kompozicijos |
| CA2647592C (en) * | 2006-05-26 | 2014-01-28 | Abbott Laboratories | Inhibitors of polo-like kinases |
| PE20080368A1 (es) * | 2006-06-12 | 2008-05-16 | Schering Corp | Sales y formulaciones de 2-hidroxi-n,n-dimetil-3-[[2-[[1(r)-5-metil-2-furanil)propil]amino]-3,4-dioxi-1-ciclobuteno-1-il]amino]benzamida como antagonista selectivo ya sea del receptor cxcr2 o ambos, cxcr1 y cxcr2 |
| CN101511809A (zh) * | 2006-07-07 | 2009-08-19 | 先灵公司 | 作为cxc-趋化因子受体配体的3,4-二取代的环丁烯-1,2-二酮 |
| US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| EA200901612A1 (ru) | 2007-06-06 | 2010-06-30 | Новартис Аг | Противовоспалительные соединения замещенных циклобутендионов |
| EP2178826B1 (en) * | 2007-07-03 | 2017-05-17 | Merck Sharp & Dohme Corp. | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| WO2009156421A1 (en) * | 2008-06-24 | 2009-12-30 | Topotarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| WO2010063802A1 (en) * | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| CA2799154A1 (en) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Indazole inhibitors of kinase |
| FR2961695B1 (fr) | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| KR101916489B1 (ko) | 2011-01-07 | 2018-11-07 | 알러간, 인코포레이티드 | 멜라닌 변형 조성물들 및 이의 사용 방법들 |
| PT2760821T (pt) | 2011-09-02 | 2018-01-11 | Novartis Ag | Sal de colina de um composto anti-inflamatório de ciclobutenodiona substituída |
| FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981936B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981935B1 (fr) | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| CN103242210B (zh) * | 2012-02-09 | 2014-09-24 | 北京艾百诺科技有限公司 | 含有取代方酸的乙酸妙林酯及其应用 |
| JP6134376B2 (ja) | 2012-03-16 | 2017-05-24 | アクシキン ファーマシューティカルズ インコーポレーテッド | ３，５−ジアミノピラゾールキナーゼ阻害剤 |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CN103382192A (zh) * | 2012-05-04 | 2013-11-06 | 同创医药(苏州)有限公司 | N-单取代哌嗪衍生物的制备 |
| US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CN103214327A (zh) * | 2013-03-22 | 2013-07-24 | 郑州泰基鸿诺药物科技有限公司 | 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法 |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| FR3030515B1 (fr) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| AU2015369690B2 (en) | 2014-12-23 | 2019-01-17 | SMA Therapeutics Inc. | 3,5-diaminopyrazole kinase inhibitors |
| TWI724056B (zh) * | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) * | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
| AU2018318075B2 (en) * | 2017-08-14 | 2023-04-13 | Allergan, Inc. | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof |
| WO2019067332A1 (en) | 2017-09-27 | 2019-04-04 | Merck Sharp & Dohme Corp. | COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST |
| AU2019205786B2 (en) | 2018-01-08 | 2023-12-14 | Chemocentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2 |
| EP3852879A1 (en) | 2018-09-21 | 2021-07-28 | Pfizer Inc. | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors |
| CN110041309B (zh) * | 2019-04-04 | 2022-01-28 | 广东工业大学 | 一种2-羧基哌嗪连接的他克林-8-氨基(羟基)喹啉衍生物及制备与应用 |
| CN114727993B (zh) * | 2019-10-07 | 2025-11-14 | D·E·萧尔研究有限责任公司 | 作为Kv1.3钾SHAKER通道阻断剂的芳基亚甲基杂环化合物 |
| KR102710925B1 (ko) * | 2021-06-01 | 2024-09-27 | 부산대학교 산학협력단 | 신규 스퀘어아마이드 유도체 및 이의 용도 |
| CN118339161B (zh) * | 2021-12-10 | 2025-12-09 | 正大天晴药业集团股份有限公司 | 一种异噻唑并[5,4-d]嘧啶类IRAK4抑制剂的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000035855A1 (en) * | 1998-12-14 | 2000-06-22 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0692915A (ja) * | 1992-07-28 | 1994-04-05 | Sumitomo Metal Ind Ltd | １，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途 |
| GB9312210D0 (en) * | 1993-06-14 | 1993-07-28 | Smithkline Beecham Plc | Chemical compounds |
| GB9316111D0 (en) * | 1993-08-04 | 1993-09-22 | Pfizer Ltd | Benzopyrans |
| US5354763A (en) * | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5466712A (en) * | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| HU218794B (hu) * | 1994-11-16 | 2000-12-28 | American Home Products Corporation | Diamino-ciklobutén-3,4-dionok, előállításuk és ezeket tartalmazó gyógyszerkészítmények |
| WO1997049286A1 (en) * | 1996-06-27 | 1997-12-31 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| US5840764A (en) * | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| WO1998033763A1 (en) * | 1997-01-30 | 1998-08-06 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| US6211220B1 (en) * | 1998-11-23 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives |
| CN1334801A (zh) * | 1998-12-16 | 2002-02-06 | 拜尔公司 | 作为整联蛋白拮抗剂的新的联苯基和类似联苯基的化合物 |
| US6518283B1 (en) * | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| AR033803A1 (es) * | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| WO2001092202A1 (en) * | 2000-05-30 | 2001-12-06 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| ES2276926T3 (es) * | 2001-01-16 | 2007-07-01 | Smithkline Beecham Corporation | Antagonistas del receptor de il-8. |
| CN1529591A (zh) * | 2001-03-30 | 2004-09-15 | ʷ��˿�������ȳ�ķ����˾ | 含苯酚化合物的合成方法 |
| WO2003080053A1 (en) * | 2002-03-18 | 2003-10-02 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
-
2002
- 2002-04-15 CZ CZ20032831A patent/CZ20032831A3/cs unknown
- 2002-04-15 WO PCT/US2002/012681 patent/WO2002083624A1/en not_active Ceased
- 2002-04-15 SI SI200230898T patent/SI1818325T1/sl unknown
- 2002-04-15 PL PL390082A patent/PL208928B1/pl unknown
- 2002-04-15 BR BRPI0208957 patent/BRPI0208957B8/pt not_active IP Right Cessation
- 2002-04-15 MX MXPA03009441A patent/MXPA03009441A/es active IP Right Grant
- 2002-04-15 IL IL15826202A patent/IL158262A0/xx unknown
- 2002-04-15 CN CNB028119797A patent/CN1289471C/zh not_active Expired - Fee Related
- 2002-04-15 EP EP02739172A patent/EP1381590B1/en not_active Expired - Lifetime
- 2002-04-15 NZ NZ529551A patent/NZ529551A/en not_active IP Right Cessation
- 2002-04-15 AR ARP020101371A patent/AR035825A1/es not_active Application Discontinuation
- 2002-04-15 EP EP07010711A patent/EP1818325B1/en not_active Expired - Lifetime
- 2002-04-15 DE DE60235507T patent/DE60235507D1/de not_active Expired - Lifetime
- 2002-04-15 MY MYPI20021372A patent/MY138202A/en unknown
- 2002-04-15 DE DE60220778T patent/DE60220778T2/de not_active Expired - Lifetime
- 2002-04-15 AU AU2002311841A patent/AU2002311841B2/en not_active Expired
- 2002-04-15 CN CNA2006101374093A patent/CN1990457A/zh active Pending
- 2002-04-15 PT PT02739172T patent/PT1381590E/pt unknown
- 2002-04-15 AT AT02739172T patent/ATE365154T1/de active
- 2002-04-15 SI SI200230572T patent/SI1381590T1/sl unknown
- 2002-04-15 NZ NZ560453A patent/NZ560453A/en unknown
- 2002-04-15 SK SK1288-2003A patent/SK287598B6/sk not_active IP Right Cessation
- 2002-04-15 KR KR1020037013527A patent/KR100952531B1/ko not_active Expired - Fee Related
- 2002-04-15 PT PT07010711T patent/PT1818325E/pt unknown
- 2002-04-15 AT AT07010711T patent/ATE458715T1/de active
- 2002-04-15 ES ES07010711T patent/ES2340207T3/es not_active Expired - Lifetime
- 2002-04-15 MY MYPI20070922A patent/MY149050A/en unknown
- 2002-04-15 NZ NZ543869A patent/NZ543869A/en not_active IP Right Cessation
- 2002-04-15 HU HU0401783A patent/HUP0401783A3/hu unknown
- 2002-04-15 DK DK07010711.5T patent/DK1818325T3/da active
- 2002-04-15 RU RU2003133448/04A patent/RU2344123C9/ru not_active IP Right Cessation
- 2002-04-15 PL PL367129A patent/PL207255B1/pl unknown
- 2002-04-15 DK DK02739172T patent/DK1381590T3/da active
- 2002-04-15 CA CA2444031A patent/CA2444031C/en not_active Expired - Lifetime
- 2002-04-15 ES ES02739172T patent/ES2287284T3/es not_active Expired - Lifetime
- 2002-04-15 KR KR1020097026265A patent/KR20100008794A/ko not_active Ceased
- 2002-04-15 JP JP2002581381A patent/JP4499993B2/ja not_active Expired - Lifetime
- 2002-04-16 PE PE2002000318A patent/PE20021084A1/es not_active Application Discontinuation
- 2002-04-16 TW TW091107670A patent/TWI316930B/zh active
- 2002-04-16 TW TW096102669A patent/TW200736196A/zh unknown
-
2003
- 2003-10-02 IL IL158262A patent/IL158262A/en not_active IP Right Cessation
- 2003-10-09 ZA ZA2003/07905A patent/ZA200307905B/en unknown
- 2003-10-15 NO NO20034612A patent/NO330790B1/no not_active IP Right Cessation
- 2003-10-16 EC EC2003004809A patent/ECSP034809A/es unknown
-
2006
- 2006-08-24 AU AU2006203679A patent/AU2006203679A1/en not_active Abandoned
-
2007
- 2007-08-07 CY CY20071101059T patent/CY1109908T1/el unknown
-
2009
- 2009-05-20 JP JP2009122594A patent/JP2009179641A/ja active Pending
- 2009-10-25 IL IL201754A patent/IL201754A0/en unknown
- 2009-12-08 JP JP2009278869A patent/JP5294418B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-29 CY CY20101100380T patent/CY1109989T1/el unknown
- 2010-08-20 AU AU2010212484A patent/AU2010212484B2/en not_active Expired
-
2011
- 2011-01-12 NO NO20110050A patent/NO20110050L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000035855A1 (en) * | 1998-12-14 | 2000-06-22 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2784831C2 (ru) * | 2018-09-21 | 2022-11-30 | Пфайзер Инк. | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, пригодные в качестве ингибиторов ccr6 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2344123C9 (ru) | 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| RU2020115095A (ru) | Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2 | |
| AU2020275818B2 (en) | Fluorine-containing compound and anti-cancer medical use thereof | |
| RU2363700C2 (ru) | Производные хинуклидина и фармацевтические композиции, содержащие их | |
| RU2003130268A (ru) | Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью | |
| JP2006515858A5 (enExample) | ||
| JP2004535447A5 (enExample) | ||
| JP2004532846A5 (enExample) | ||
| JP2004529140A5 (enExample) | ||
| CA2496676A1 (en) | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands | |
| JP2011509309A5 (enExample) | ||
| JP2010514842A5 (enExample) | ||
| JP2019507736A5 (enExample) | ||
| WO2000061559A1 (en) | N-substituted cyanoguanidine compounds | |
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| SG188217A1 (en) | 1,5-diphenyl-penta-1,4-dien-3-one compounds | |
| FR2585019A1 (fr) | Derives de distamycine et leur procede de fabrication | |
| JPWO2020247496A5 (enExample) | ||
| JP4707393B2 (ja) | 抗癌化合物 | |
| RU2008143556A (ru) | Производные тиазолилдигидроиндазола в качестве ингибиторов протеинкиназ | |
| JP2024112835A5 (enExample) | ||
| RU2019109570A (ru) | 8-(азетидин-1-ил)-[1,2,4]триазоло[1,5-а]пиридинилы, композиции и способы их применения | |
| RU2380369C2 (ru) | Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Reissue of patent specification | ||
| PD4A | Correction of name of patent owner | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150416 |